Histological subtype is the most important determinant of survival in metastatic papillary thyroid cancer

被引：22

作者：

Chrisoulidou A. ^{[1
]}

Boudina M. ^{[1
]}

Tzemailas A. ^{[2
]}

Doumala E. ^{[1
]}

Iliadou P.K. ^{[1
]}

Patakiouta F. ^{[3
]}

Pazaitou-Panayiotou K. ^{[1
]}

机构：

[1] Department of Endocrinology and Endocrine Oncology, Theagenio Cancer Hospital

[2] Department of Nuclear Medicine, Theagenio Cancer Hospital

[3] Department of Pathology, Theagenio Cancer Hospital, Thessaloniki

来源：

Thyroid Research | / 4卷 / 1期

关键词：

distant metastases; papillary thyroid carcinoma;

D O I：

10.1186/1756-6614-4-12

中图分类号：

学科分类号：

摘要：

Background: Papillary thyroid cancer (PTC) comprises the commonest type of thyroid cancer and carries the highest rate of survival. However, when metastatic disease occurs, survival is significantly affected. Methods. We aimed to identify prognostic histopathological and clinical factors that modify survival in metastatic PTC. All cases of metastatic PTC treated at our department in the last 20 years were reviewed and analyzed. Results: Histological subtype was the most important determinant of survival, as classic PTC demonstrated clearly improved survival compared to follicular subtype of PTC and other less frequently seen histological subtypes. The instant risk of death for the other histological subtypes was 4.56 times higher than the risk for the classic papillary type. Overall, a 10-year survival of 76.6% in our patients was seen. Conclusions: Patients with aggressive variants of PTC are more at risk for the development of metastatic disease. In these patients, established treatment modalities (surgery, radioiodine therapy) should be offered promptly, as well as close follow-up. © 2011 Chrisoulidou et al; licensee BioMed Central Ltd.

引用

共 26 条

[1]

Salter K.D., Andersen P.E., Cohen J.I., Schuff K.G., Lester L., Shindo M.L., Sauer D., Gross N.D., Central node metastases in papillary thyroid carcinoma based on tumor histologic type and focality, Arch Otolaryngol Head Neck Surg, 136, pp. 692-696, (2010)

[2]

Maxon H.R., Smith H.S., Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer, Endocrinol Metab Clin North Am, 19, pp. 685-671, (1990)

[3]

Sugitani I., Fujimoto Y., Yamamoto N., Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control, Surgery, 143, 1, pp. 35-42, (2008)

[4]

Lang B.H.-H., Lo C.-Y., Chan W.-F., Lam A.K.-Y., Wan K.-Y., Classical and follicular variant of papillary thyroid carcinoma: A comparative study on clinicopathologic features and long-term outcome, World Journal of Surgery, 30, 5, pp. 752-758, (2006)

[5]

Lin J.-D., Chao T.-C., Chou S.-C., Hsueh C., Papillary thyroid carcinomas with lung metastases, Thyroid, 14, 12, pp. 1091-1096, (2004)

[6]

Do M.Y., Rhee Y., Kim D.J., Kim C.S., Nam K.H., Ahn C.W., Cha B.S., Kim K.R., Lee H.C., Park C.S., Lim S.K., Clinical features of bone metastases resulting from thyroid cancer: A review of 28 patients over a 20-year period, Endocrine Journal, 52, 6, pp. 701-707, (2005)

[7]

Parker L.N., Wu S.-Y., Kim D.D., Recurrence of papillary thyroid carcinoma presenting as a focal neurologic deficit, Archives of Internal Medicine, 146, 10, pp. 1985-1987, (1986)

[8]

Holmquest D.L., Lake P., Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-131, J Nucl Med, 17, pp. 307-309, (1976)

[9]

Agriantonis D.J., Hall L., Wilson M.A., Utility of SPECT/CT as an adjunct planar whole body I-131 imaging: Liver metastases from papillary thyroid cancer, Clin Nucl Med, 34, pp. 247-248, (2009)

[10]

Mizukami Y., Michigishi T., Nonomura A., Hashimoto T., Terahata S., Noguchi M., Hisada K.-I., Matsubara F., Distant metastases in differentiated thyroid carcinomas: A clinical and pathologic study, Human Pathology, 21, 3, pp. 283-290, (1990)

← 1 2 3 →